Fortress Biotech Inc

Fortress Biotech reported second quarter 2026 financial results, with total revenue of $18.5 million compared to $15 million in the second quarter of 2025, reflecting a 23% increase from period to period. The company's GAAP net loss narrowed to $300,000 or $0.01 per share basic and diluted compared to a net loss of $3.8 million or $0.16 per share basic and diluted for 2Q 2025. Emrosi net revenue was $8.1 million, driven by sequential prescription growth and improved payer reimbursement, with total prescriptions reaching 36,000, a 20% sequential increase from approximately 30,000 in the first quarter of 2026. Unique prescribers grew to 4,500, a 40% increase from 3,200 at the end of 2025, and high-quality payer coverage rose to 38% of commercial lives from 34% in the prior quarter. The company ended the quarter with $196.6 million in cash and cash equivalents, up from $79.4 million at the end of 2025, following the monetization of a Priority Review Voucher.